Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, June 14, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Robert Burns Maintained (ATRA) at Strong Buy with Increased Target to $700 on, Jun 14th, 2023
Robert Burns of HC Wainwright & Co., Maintained "Atara Biotherapeutics, Inc." (ATRA) at Strong Buy with Increased Target from $675 to $700 on, Jun 14th, 2023.
Robert has made no other calls on ATRA in the last 4 months.
There is 1 other peer that has a rating on ATRA. Out of the 1 peers that are also analyzing ATRA, 0 agree with Robert's Rating of Hold.
This is the rating of the analyst that currently disagrees with Robert
- John Newman of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $500 on, Tuesday, May 9th, 2023
